Tuğba BAŞOĞLU, Kadriye Ebru AKAR, Pelin BAĞCI, Nalan AKGÜL BABACAN, Mehmet Akif ÖZTÜRK, Fatih Emin ÖZTÜRK, Nazım Can DEMİRCAN, Rukiye ARIKAN, Tuğba AKIN TELLİ, Özlem ERCELEP, Faysal DANE, Perran Fulden YUMUK

Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma

Background: Pancreatic ductal adenocarcinoma differs from other solid tumors with its unique immunosuppressive microenvironment and non-immunogenic feature. There are not many studies in the literature investigating the effect of these features on prognosis. Aims: To investigate the prognostic value of tissue-resident memory T cells, tumor microenvironment features, and tumor-associated immune cells in resected pancreatic ductal adenocarcinomas. Study Design: Retrospective cross-sectional study. Methods: Of 138 patients diagnosed with pancreatic ductal adenocarcinoma between 2011 and 2018, 81 were included in the study. Specimens from operated patients were reassessed separately as peritumoral and intratumoral areas for tissue resident memory cells and tumor microenvironmental elements (tumor infiltrating lymphocytes, tumor stroma, CD204+ macrophages, PDL1+ immune cells). Disease-free survival and overall survival were defined from the date of operation to the date of recurrence and the date of first diagnosis to the date of death, respectively. If the patient was alive, the last visit date was taken into account. Results: The median age at diagnosis was 63 (range: 40-78). The median follow-up period was 18.9 months (range: 1.4-80.4 months). Median overall survival was 23.7 months (1.4-80.4 months) and median disease-free survival was 10.8 months (1.4-74.4 months). Patients with higher intra-tumoral tissue-resident memory cell counts had a longer survival trend than those having lower values (25.6 months vs. 18 months, respectively, P = .84). According to microenvironmental evaluations, lower stromal score (defined as stroma having less desmoplasia and rich in cells) and presence of peritumoral Crohn’s-like inflammatory response were associated with higher survival (29.2 months vs. 19.7 months for low vs. high stromal scores, respectively, P = .16 and 30.2 months vs. 18.1 months for the presence of Crohn’s-like inflammatory response P = .13). Decreased survival was observed in tumors with increased CD204+ tumor associated macrophages which were immunosuppressive elements of the microenvironment (12 months vs. 26.3 months for intra-tumoral assessment, P = .29). Conclusion: Tissue-resident memory T cells and other microenvironmental features may be prognostic in resectable pancreatic ductal adenocarcinomas. Further studies with larger cohorts are needed for validation.

PDF

___

1. Stewart BW, Kleihues P. World Cancer Report 2003. Lyon, France: International Agency for Research on Cancer (IARC); 2003. [CrossRef]
2. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418-429. [CrossRef]
3. Bonaventura P, Shekarian T, Alcazer V, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. [CrossRef]
4. Lohneis P, Sinn M, Bischoff S, et al. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer. 2017;83:290-301. [CrossRef]
5. Peranzoni E, Lemoine J, Vimeux L, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment. Proc Natl Acad Sci USA. 2018;115(17):E4041-E4050. [CrossRef]
6. Jiang X. Skin-delivered vaccines. Sci-Bus Exch. 2012;5(12):319. [CrossRef]
7. Zhou YW, Komada Y, Inaba H, et al. Functional significance of adhesion molecules in Fas-dependent apoptotic cell death induced by interleukin-2-activated T cells. Immunol Invest. 1998;27(4-5):309-322. [CrossRef]
8. Karayiannakis AJ, Syrigos KN, Chatzigianni E, et al. Aberrant E-cadherin expression is associated with loss of differentiation and advanced stage in human pancreatic cancer. Anticancer Res. 1998;18(6A):4177-4180. [CrossRef]
9. Kilshaw PJ, Murant SJ. A new surface antigen on intraepithelial lymphocytes in the intestine. Eur J Immunol. 1990;20(10):2201-2207. [CrossRef]
10. May TMT. Breaking advances. Cancer Res. 2011;71:291-626.
11. Djenidi F, Adam J, Goubar A, et al. CD8+ CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol. 2015;194:3475-3486. [CrossRef]
12. ByrneA, Savas P, Sant S, et al. Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nat Rev Clin Oncol. 2020;17(6):341-348. [CrossRef]
13. Park SL, Buzzai A, Rautela J, et al. Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin. Nature. 2019;565(7739):366-371. [CrossRef]
14. Webb JR, Milne K, Watson P, DeLeeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20(2):434-444. [CrossRef]
15. Quinn E, Hawkins N, Yip YL, Suter C, Ward R. CD103+ intraepithelial lymphocytes—a unique population in microsatellite unstable sporadic colorectal cancer. Eur J Cancer. 2003;39(4):469-475. [CrossRef]
16. Mami-Chouaib F, Blanc C, Corgnac S, et al. Resident memory T cells, critical components in tumor immunology. J Immunother Cancer. 2018;6(1):87. [CrossRef]
17. Nizard M, Roussel H, Diniz MO, et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun. 2017;8(1):15221. [CrossRef]
18. Edwards J, Wilmott JS, Madore J, et al. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti–PD-1 treatment. Clin Cancer Res. 2018;24(13):3036- 3045. [CrossRef]
19. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-78. [CrossRef]
20. Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011;167(2):e211-e219. [CrossRef]
21. Hirayama S, Ishii G, Nagai K, et al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of CD204- positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol. 2012;7(12):1790-1797. [CrossRef]
22. Alexander BJD, Brett WB, Andrew MB, George GBPL, Frank S, Raja RS. Template for reporting results of quantitative IHC biomarker testing of specimens from patients with carcinoma. version 1.0.0.0. Illinois, USA: College of American Pathologists; 2021. https://documents.cap.org/protocols/IHC.Bmk_1.0.0.0.REL_CAPCP.pdf [CrossRef]
23. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-2406. [CrossRef]
24. Miksch RC, Schoenberg MB, Weniger M, et al. Prognostic impact of tumor infiltrating lymphocytes and neutrophils on survival of patients with upfront resection of pancreatic cancer. Cancers. 2019;11(1). [CrossRef]
25. Ino Y, Oguro S, Yamazaki-Itoh R, Hori S, Shimada K, Hiraoka N. Reliable evaluation of tumor-infiltrating lymphocytes in pancreatic cancer tissue biopsies. Oncotarget. 2019;10(10):1149-1159. [CrossRef]
26. Graham DM, Appelman HD. Crohn’s-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator. Mod Pathol. 1990;3(3):332-335. [CrossRef]
27. Maoz A, Dennis M, Greenson JK. The Crohn’s-like lymphoid reaction to colorectal cancer-tertiary lymphoid structures with immunologic and potentially therapeutic relevance in colorectal cancer. Front Immunol. 2019;10:1884. [CrossRef]
28. Cannon A, Thompson C, Hall BR, Jain M, Kumar S, Batra SK. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Genes Cancer. 2018;9(3-4):78-86. [CrossRef]
29. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756-2761. [CrossRef]
30. Lu C, Paschall AV, Shi H, et al. The MLL1-H3K4me3 axis-mediated PD-L1 expression and pancreatic cancer immune evasion. J Natl Cancer Inst. 2017;109(6). [CrossRef]
31. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563-567. [CrossRef]
32. Zhao L, Cao Y. PD-L1 expression level displays a positive correlation with immune response in pancreatic cancer. Dis Markers. 2020;2020:8843146. [CrossRef]
33. Yamashita K, Iwatsuki M, Harada K, et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020;23(1):95-104. [CrossRef]
34. Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330-337. [CrossRef]
35. Hu Y, Chen W, Yan Z, Ma J, Zhu F, Huo J. Prognostic value of PD-L1 expression in patients with pancreatic cancer: a PRISMA-compliant meta-analysis. Med. 2019;98(3):e14006. [CrossRef]